RecruitingNCT06111807

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

GUIding Multi-moDal thErapies Against MRD by LiquidBiopsies in Non Small Cell Lung Cancer- GUIDE.MRD-03-NSCLC

Sponsor

University Medical Center Groningen

Enrollment

248 participants

Start Date

Nov 10, 2023

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Stage III

Summary

Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. GUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study validates blood tests that detect circulating tumor DNA (ctDNA) — fragments of cancer DNA in the bloodstream — in patients with stage III non-small cell lung cancer (NSCLC). The goal is to see if these tests can reliably track disease response and detect recurrence after treatment. **You may be eligible if...** - You are 18 or older with clinical stage III non-small cell lung cancer (no confirmed distant spread) - You are scheduled for curative-intent treatment (surgery and/or radiation therapy) - Sufficient tumor tissue is available for testing - You are able to give informed consent and attend follow-up visits **You may NOT be eligible if...** - You have confirmed distant metastases - You have another active cancer at the same time (exceptions: some skin cancers, or cancers treated curatively 5+ years ago) - Sufficient tumor tissue is not available Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.